Vitamin D Estimation With Giardia Lamblia Infections

February 27, 2021 updated by: Mohamed Sayed Farrag, Sohag University

Estimation of Vitamin D in Humans Infected With Giardia Lamblia

investigators will take stool and blood samples from two groups of humans :-

1-group A (healthy group negative Giardia or control group),2-group B (positive Giardia or case group)then investigators make estimation for vitamin D in both groups then investigators try to find if there is relation between vitamin D level and Giardia lamblia infections

Study Overview

Status

Unknown

Conditions

Detailed Description

In this research a case- control study will be used) ,the percentage of case to control will be 1:1 the total number of samples 192 ,investigators will take stool and blood samples from two groups of humans :-

1-group A (healthy group negative Giardia or control group),2-group B (positive Giardia or case group)then investigators make estimation for vitamin D in both groups then investigators try to find if there is relation between vitamin D level and Giardia lamblia infections

Study Type

Observational

Enrollment (Anticipated)

192

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Noha sammer ahmed, assist prof
  • Phone Number: 01273126001

Study Locations

  • Egypt
      • Sohag, Egypt
        • Recruiting
        • Faculty of medicine
        • Contact:
        • Contact:
          • Noha sammer ahmed, assist prof
          • Phone Number: 01273126001
        • Principal Investigator:
          • Mohammed sayed farrag, demonstrator
      • Sohag, Egypt
        • Recruiting
        • faculty of medicine Sohag university
        • Contact:
        • Principal Investigator:
          • Mohammed sayed farrag, demonstrator

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

we take 192 samples then we will divide these samples into two groups :-

  1. Group A (healty group with negative Giardia lamblia or control group)
  2. Group B ( diseased group with positive Giardia lamblia or cases group)

Description

Inclusion Criteria:

  • patient infected with Giardia lamblia.

Exclusion Criteria:

  • patient takes vitamin D supplement - patient has kidney disease- patient has liver disease-patient has a debilitating disease disease such as cancer or diabetes.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group A
1-Group A(Healty group with negative Giardia lamblia or control group) 96 samples
Group B
2- Group B(Cases group with positive Giardia lamblia )96 sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
fluctuation level of vitamin D level
Time Frame: 1 year
Estimation of vitamin D level in humans infected with Giardia lamblia
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Investigators

  • Principal Investigator: Mohammed Sayed Farrag, Demonstrator, faculty of medicine Sohag university
  • Study Director: Mohammed Sayed Farrag, Demonstrator, faculty of medicine Sohag university

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 17, 2021

Primary Completion (Anticipated)

February 1, 2022

Study Completion (Anticipated)

February 1, 2022

Study Registration Dates

First Submitted

February 25, 2021

First Submitted That Met QC Criteria

February 27, 2021

First Posted (Actual)

March 3, 2021

Study Record Updates

Last Update Posted (Actual)

March 3, 2021

Last Update Submitted That Met QC Criteria

February 27, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-21-02-17

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Giardia Lamblia Infection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe